Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiaomeng, Manner, Karl, DeJesus, Rowena, White, Kathy, Gattis, Corie, Ngo, Priscilla, Bandoro, Christopher, Tham, Eleonore, Chu, Elaine Y., Young, Chi, Wells, Frank, Basco, Ronald, Friera, Annabelle, Kangeyan, Divy, Beauchesne, Pascal, Dowdle, William E., Deuse, Tobias, Fry, Terry J., Foster, Aaron E., Schrepfer, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086027/
https://www.ncbi.nlm.nih.gov/pubmed/37037829
http://dx.doi.org/10.1038/s41467-023-37785-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086027/
https://www.ncbi.nlm.nih.gov/pubmed/37037829
http://dx.doi.org/10.1038/s41467-023-37785-2

Ejemplares similares